Tuberculosis - Learning the Effect of Parasites and Reinforcing Diets

NCT ID: NCT05048485

Last Updated: 2025-11-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

141 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-04-09

Study Completion Date

2025-07-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objectives of this research are to determine:

* the burden of intestinal parasitic infections among persons living with pulmonary tuberculosis (TB)
* whether intestinal parasitic infections alter TB treatment outcomes, including speed of sputum clearance and treatment outcomes
* the impact of malnutrition on speed of sputum clearance and TB treatment outcomes
* whether nutritional supplementation improves speed of sputum clearance and treatment outcomes

In this study the researchers will investigate how intestinal parasites impact the nutritional status of TB patients before the start of nutritional supplementation and how they alter the trajectory of weight gain in those receiving supplementation by analyzing results from 2 cohorts.

LEOPARD Cohort 1-

* Control-Enroll TB cases, screen for undernutrition, obtain stool for intestinal parasite screening by polymerase chain reaction (PCR), and assess them for treatment outcomes and weight gain
* TB LION (Learning Impact of Nutrition) - Enroll TB cases, provide nutritional supplementation for 6 months (as part of existing TB LION study), screen for undernutrition, obtain stool for intestinal parasite screening by PCR, and assess them for treatment outcomes and weight gain

LEOPARD Cohort 2 -

* Enroll TB cases, screen for undernutrition, obtain stool for internal parasite screening by PCR, and assess them for treatment outcomes and weight gain.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

LEOPARD Cohort 1-

Control:

* Pulmonary TB patients who are newly diagnosed smear-positive (\>/=1+ Acid-fast bacillus/AFB) and whose household contacts are enrolled in the TB-LION (Learning Impact of Nutrition) study but are not receiving nutritional supplementation
* 50 participants will be enrolled and followed for up to 12 months
* Stool sample will be collected at the week 1 visit (visit 2)
* Blood samples will be collected the screening visit, week 1, month 2, and month 6
* Sputum samples will be collected at the screening visit, week 1, week 2, and month 6

TB LION:

* Pulmonary TB patients who are newly diagnosed smear-positive (\>/=1+ AFB) and whose household contacts are enrolled in the TB-LION study and are receiving nutritional supplementation
* 50 participants will be enrolled and followed for up to 12 months
* Index case and rest of household will receive nutritional supplementation for 6 months
* Stool sample will be collected at the week 1 visit (visit 2)
* Blood samples will be collected at the screening visit, week 1, month 2, and month 6
* Sputum samples will be collected at the screening visit, week 1, week 2, and month 6

LEOPARD Cohort 2-

* Pulmonary TB patients who are newly diagnosed smear-positive (\>/=1+ AFB) and whose household contacts are not enrolled in the TB-LION study
* 300 participants will be enrolled and followed for up to 6 months
* Stool sample will be collected at the week 1 visit (visit 2)
* Blood samples will be collected at the screening visit and week 1
* Sputum samples will be collected at the screening visit, week 1, and week 2

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Malnutrition Tuberculosis, Pulmonary Helminthiasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LEOPARD Cohort 1

Control group: The study will enroll 50 newly diagnosed smear-positive (\>/=1+ AFB) pulmonary TB patients whose household contacts are enrolled in the TB-LION study and who are not receiving nutritional supplementation.

TB LION group: The study will enroll 50 newly diagnosed smear-positive (\>/=1+ AFB) pulmonary TB patients whose household contacts are enrolled in the TB-LION study and who are receiving nutritional supplementation.

No interventions assigned to this group

LEOPARD Cohort 2

The study will enroll 300 newly diagnosed smear-positive (\>/=1+ AFB) pulmonary TB patients whose household contacts are not enrolled in the TB-LION study.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Sputum Ziehl-Neelsen stain positive for AFB (≥1+)
* Culture or Xpert positive for Mtb; those who are smear+ but ultimately Xpert or culture negative, will be included until their culture results return at which time they will retrospectively be removed from the study.
* No history of TB treatment (i.e., no history of partial or complete treatment for a previous TB episode)
* Has at least 1 household contact with whom they have shared a house with during the previous one month
* Agrees to have household contact notified about study

Exclusion Criteria

* Household contact ineligible for TB LION study
* Pregnant at enrollment
* Previously diagnosed with diabetes or hemoglobin A1c\>6.5% on testing
* No Xpert or culture confirmation and unable to provide sputum sample
* Known multidrug-resistant tuberculosis (MDR) or extensively drug resistant (XDR) TB case at recruitment or found at time of enrollment
* BMI \<14 kg/m2
* Lower extremity edema/kwashiorkor
* Reported neuropathy in lower extremities (may result from thiamine deficiency)
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Jawaharlal Institute of Postgraduate Medical Education & Research

OTHER_GOV

Sponsor Role collaborator

Boston Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pranay Sinha, MD

Role: PRINCIPAL_INVESTIGATOR

Boston Medical Center

Pakrash Babu Narasimhan, PhD

Role: PRINCIPAL_INVESTIGATOR

Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER)

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Boston Medical Center

Boston, Massachusetts, United States

Site Status

Jawaharlal Institute of Postgraduate Medical Education and Research

Puducherry, , India

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States India

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

H-41912

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

H-41912

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Prevention of Tuberculosis in Prisons
NCT03028129 TERMINATED PHASE4
Expand New Drugs for TB [endTB]
NCT03259269 COMPLETED
Deworming Against Tuberculosis
NCT00857116 COMPLETED NA